Deal Diligence #003 — Med Spa AZ at 8.33x EBITDA on a 60% Margin

Preheader: Deep dive on the highest-priced listing in Issue 004. Why the reported 60% EBITDA margin is structurally implausible for a physical service business, where the asking price actually sits relative to fair value, and what a buyer who reads service business listings carefully should pay.

A medical spa located in Gilbert, Arizona came to market this week at $25.0M asking on $3.0M reported EBITDA. The implied multiple is 8.33x EBITDA, the highest non-real-estate-inclusive multiple in the Issue 004 sample of 22 valid US listings. The sample median for the week was 3.82x. Comparable med spa businesses in the SBA-range typically transact between 4x and 6x EBITDA depending on customer mix, geographic exposure, and earnings durability. An 8.33x multiple is approximately 67% above the category midpoint.

The headline numbers, as disclosed:

A 60% EBITDA margin on a physical service business with seven medical-grade devices, eight skilled-labor employees, and a leased commercial space is not a number that survives normalization. Med spas in the United States typically report EBITDA margins between 15% and 25%, with top-decile operators reaching 25-35% after aggressive cost discipline. A 60% reported margin indicates one of three things: the founder is operating at zero or nominal compensation, multiple cost categories have been treated as add-backs that will not survive lender review, or both.

This Deep Dive is about deconstructing how the headline EBITDA was constructed, what the sustainable EBITDA actually looks like, and what the asking price means once the trailing financial picture is reset to defensible numbers. The 8.33x multiple is not the market multiple. It is the seller's preferred normalization of a price that, against any reasonable normalized EBITDA, sits substantially higher than category norm.

The first signal is the listing's positioning language. "Number 1 Gross Med Spa in Nation" and "Award Winning" are common broker framings for premium-priced listings in personal services categories. Neither term has a verifiable source on the cover sheet. "Number 1 Gross" is a specific superlative that should be traceable to an industry ranking source; absent such citation, it functions as marketing language rather than verified fact. "Award Winning" without specification of which awards, in which years, awarded by which organizations, is similar.

The operational profile, by contrast, is concrete. Seven medical-grade devices, two registered nurse injectors, and six laser technicians describes a meaningful clinical operation. The device count alone implies substantial capital investment: medical-grade aesthetic lasers (CO2 fractional, IPL, cooling lasers, body contouring devices) typically cost between $80,000 and $300,000 each at acquisition. A seven-device operation reflects $1M to $2M in original equipment cost.

Revenue of $5.0M across this operational footprint produces approximately $625K of revenue per skilled-labor employee, which is reasonable for a busy med spa with multiple service modalities. Revenue per device is approximately $715K annually, also reasonable for high-utilization equipment.

The math up to this point is internally consistent. The operational profile supports the $5M revenue figure. Where the math breaks is the conversion from $5M revenue to $3M EBITDA.

The cost categories that appear in any med spa P&L include: staff wages and benefits (8+ skilled employees plus front-desk, scheduling, and management), medical director fees (required by Arizona regulation for non-physician-owned med spas, typically $3K-$10K per month), product costs (injectables alone typically run 20-30% of injection revenue at retail), device depreciation or lease costs, lease and utilities for the physical space, marketing spend, professional services (legal, accounting, compliance), insurance (medical malpractice, general liability, workers compensation), and taxes.

A defensible cost structure for a $5M-revenue med spa would allocate approximately 30-35% to staff costs, 12-18% to product costs (heavily dependent on injection mix), 4-8% to occupancy, 3-6% to marketing, 4-7% to device depreciation or lease, and 6-10% to other overhead. Total: 60-80% cost ratio, producing 20-40% EBITDA margins for well-run operations.

A 60% reported EBITDA margin implies either total costs of 40%, which is achievable only by suppressing one or more of the categories above, or revenue and earnings reporting that captures items not present in the actual operational P&L. Both possibilities exist and both warrant detailed diligence.

The most common reason a service business reports an EBITDA margin substantially above category norms is that founder labor has not been replaced in the calculation. The owner of a Gilbert, Arizona med spa with seven devices and eight skilled-labor employees is, in practice, performing one or more of the following functions: medical director oversight, sales and consultation conversion, employee management and scheduling, financial controller responsibilities, marketing direction, regulatory and compliance management.

Each of these functions has a market replacement cost. A medical director not currently being paid through the P&L would cost $50K-$120K annually if hired separately. A general manager replacing the founder's operational role would cost $80K-$140K. A controller or senior bookkeeper would cost $60K-$90K. A sales manager driving consultation-to-treatment conversion would cost $80K-$130K (often plus commission).

If the founder is currently performing the functions of a medical director, general manager, sales manager, and controller without proportionate compensation in the P&L, the labor replacement cost embedded in the reported EBITDA is approximately $300K-$500K. Subtracting this from the $3M reported EBITDA produces a normalized EBITDA of $2.5M-$2.7M, an EBITDA margin of 50-54%, still well above category norms.

The second common reason is asset depreciation treatment. Seven medical-grade devices with $1M-$2M total acquisition cost should generate $150K-$300K of annual depreciation expense over a five-to-seven-year useful life. If the devices were purchased in years prior and have been fully depreciated through the P&L, the depreciation line will be zero in the trailing twelve months, but the equivalent capital reserve required to maintain the device fleet is still $150K-$300K annually. A buyer needs to maintain or replace these devices to sustain the revenue base. The "EBITDA" figure does not capture this required reinvestment, but the buyer's lender will.

If both adjustments are applied (founder labor replacement at $400K plus device replacement reserve at $200K), normalized EBITDA falls to approximately $2.4M, producing a 48% EBITDA margin. Still above category norms but substantially closer.

The third potential explanation is that 2025 represented a single peak year for the business and the trailing twelve-month figure does not reflect a sustainable run-rate. Med spa demand was elevated during 2024-2025 across many markets, driven by post-pandemic discretionary spending recovery, growth in injectable categories (specifically GLP-1 weight management and combined aesthetic protocols), and heightened consumer marketing across the category. Operators who captured a disproportionate share of this demand may report 2025 numbers that do not project forward.

Without three to four years of P&L history, the buyer cannot distinguish a structurally high-margin operation from a peak-year aberration. The cover sheet does not provide this history. It must be requested before LOI.

The construction of headline EBITDA from operating P&L is, in the SBA-range market, a negotiated process between seller and broker. Add-backs are categories of expense that, the seller argues, would not transfer to a new owner and therefore should be added back to the reported earnings figure to produce a "normalized" EBITDA that better reflects what the buyer will inherit.

Some add-backs are universally accepted. Owner compensation that would be replaced post-close (if the owner takes a $400K salary that the new owner could replace with a $200K manager, the $200K excess is a legitimate add-back). One-time legal or professional fees tied to a specific event (litigation, transaction preparation, regulatory inquiry). Owner discretionary expenses that are personal in nature (vehicle leases for personal use, family member salaries for non-working positions, personal travel charged to the business).

Some add-backs survive lender review only with documentation. Owner travel (legitimate if business-related, not if personal). Family member compensation (legitimate if the family member performed work, not if they were ghost employees). Professional development and conferences (legitimate if industry-relevant, sometimes disallowed if luxury-coded).

Some add-backs do not survive lender review under any circumstance. Routine repair and maintenance costs that will continue post-close. Scheduled marketing spend that supports the recurring revenue base. Required regulatory compliance costs. Equipment depreciation (this is the largest single category that operators sometimes try to add back; it cannot survive lender review because the buyer must maintain the equipment fleet).

A 60% EBITDA margin in this category is consistent with a listing where multiple add-backs in the third category have been included. The buyer's first request should be the add-back schedule itself, with each add-back categorized and documented. The lender's underwriting will perform this same analysis, and the difference between the broker-stated EBITDA and the lender-recognized EBITDA is the source of substantial deal friction in cases like this.

A buyer should request this categorization on every listing reporting an EBITDA margin substantially above category norms. The Med Spa AZ listing is the strongest candidate for the analysis in the Issue 004 sample.

The listing copy referenced in industry summaries describes the price as approximately a "9x EBITDA buyout" framing. This is the seller's anchor and warrants attention in itself.

Anchoring works in transactional negotiations because the first specific number proposed shapes all subsequent numbers in the conversation. A seller who opens with $25M against a $3M reported EBITDA establishes the "9x category" as the discussion frame. A buyer who responds with "this is more like a 6x business at $18M" has already conceded the seller's frame; the negotiation is now a 6x-9x range with $18M-$25M boundaries. The buyer's actual analysis ("normalized EBITDA is $2M, market multiple is 5x, fair price is $10M") is much further from the anchor than the negotiation will likely reach.

The anchor is the seller's most important pricing tool, particularly in categories where multiples vary widely and where buyer information is asymmetric. Med spas have well-established multiple ranges in industry research (4-6x typical, 5-7x premium operations, 7x+ requiring exceptional operating evidence), but those ranges are not common knowledge among first-time buyers entering the category. A first-time buyer evaluating this listing without category research will work with the 9x frame and negotiate within it.

The seller's framing also implies a buyer profile. Listings priced at premium multiples to category norms are typically directed at strategic buyers (existing med spa chains rolling up locations) or aggressive private equity acquirers (platform investors paying premium for acquisition speed). Independent operators and search-fund buyers rarely engage at these prices because the math does not work for SBA financing. A deal in this size range, at 9x EBITDA, with $25M asking, is almost certainly being marketed to consolidation buyers willing to pay above category norms for strategic fit.

A first-time buyer or independent operator who proceeds against this listing is not the seller's target customer. The friction in negotiation will reflect that mismatch.

The buyer's task in evaluating this listing is to estimate sustainable EBITDA absent of seller framing, and to apply a defensible market multiple to that figure.

Three sustainable EBITDA scenarios:

Bull case ($2.0M sustainable, 40% margin): Founder labor partially replaceable at modest cost ($150K), devices substantially paid off but properly depreciated going forward ($150K reserve), no other normalization. Founder has built a genuinely high-margin operation through service mix optimization (high-margin injectable focus, premium pricing, strong customer retention). Implied multiple at $25M ask: 12.5x EBITDA. Even in this case, the asking price is approximately 100% above the 6x premium category multiple.

Base case ($1.5M sustainable, 30% margin): Founder labor fully replaced ($400K), proper device depreciation ($200K), normalized add-back schedule ($150K rejected). The business is a top-quartile med spa but not the structural outlier the headline implies. Implied multiple at $25M ask: 16.7x EBITDA. Asking price approximately 230% above 5x category midpoint.

Bear case ($1.1M sustainable, 22% margin): Founder labor replaced, device depreciation recognized, peak-year revenue normalized for category-wide demand softening, customer concentration risk discounted. The business is a category-typical operation with strong execution but no structural margin advantage. Implied multiple at $25M ask: 22.7x EBITDA. Asking price approximately 350% above 5x category midpoint.

The fair value range, applying 4-6x category multiple to the bear-to-bull sustainable EBITDA estimates:

A fair-value range of $4-12M against a $25M asking price is a substantial gap. The asking price is not a negotiation starting point that converges to fair value with reasonable diligence. It is a number selected for buyers in a different category (strategic consolidators paying for acquisition speed) and should not be the basis for any independent buyer's evaluation.

Documents that determine whether the listing is even financeable at any price:

Three-year P&L by month, with full cost categorization. Trailing twelve-month and three-year averages by line item.

Add-back schedule with each item categorized (universally accepted, requires documentation, will not survive lender review). Supporting documentation for every material add-back.

Owner compensation history including W-2, K-1, distributions, and discretionary expenses charged to the business. Market-rate comparable for the operational role the owner currently performs.

Three-year revenue breakdown by service category (injectables, laser treatments, body contouring, skincare retail, membership programs). Year-over-year trend by category.

Equipment list with original acquisition cost, current book value, age, and replacement cost. Depreciation schedule actually used in tax filings.

Documents that shape the price:

Customer concentration analysis. Top 20 customers by trailing-twelve-month revenue, with retention rates. Average customer lifetime value by service category.

Marketing spend by channel and customer acquisition cost trend. Med spa demand has been heavily marketing-driven and CAC trends matter for forward unit economics.

Medical director arrangement, including contract terms, monthly fees, and oversight scope. Compliance with Arizona Medical Practice Act requirements for non-physician-owned practices.

Lease terms, including remaining duration, scheduled escalations, and tenant improvement obligations. The Gilbert AZ commercial real estate market has been competitive; lease economics matter materially.

Staff retention analysis. Skilled-labor turnover (RN injectors, laser technicians, aestheticians) is the single largest operational risk in med spa transitions. Annual turnover rates for the past three years should be on the data room cover sheet.

Operational documents:

State licensing for all clinical staff. Verification of injector training and certifications.

Patient outcome and complication tracking records. Med spa businesses carry medical malpractice exposure that should be evaluated through actual incident history.

Membership program structure if any. Pre-paid services represent deferred revenue that transfers to the buyer; the deferred revenue obligation should be quantified.

The Med Spa AZ listing at $25M / 8.33x reported EBITDA is structurally mispriced for the buyer it appears to attract. The reported 60% EBITDA margin is the construction of an aggressive add-back schedule against a peak-year revenue baseline, applied to operational costs that have been suppressed through founder labor inclusion in operating performance rather than as compensation expense.

Three buyer profiles can rationalize this listing. A strategic consolidator with existing med spa operations seeking acquisition speed and willing to pay premium for that speed, where post-acquisition cost synergies recover the price premium. A private equity platform investor in the aesthetic medicine vertical executing a roll-up strategy, where premium per-acquisition pricing is justified by exit multiple expansion at platform scale. A high-net-worth individual buyer treating the acquisition as personal-use plus operating asset, where the price is partially justified by non-financial returns.

Three buyer profiles should walk away. A first-time independent operator or search-funded buyer, because the SBA lender will reject the broker-stated EBITDA and the loan-supported price will be 50-70% below ask. An operator-buyer with med spa experience but without category roll-up infrastructure, because the deal economics do not support adding this single location at this price. A financial buyer applying conventional valuation discipline, because 8.33x reported EBITDA on this margin profile produces effective multiples in the 12-23x range against any reasonable normalization, far above what the financial return profile supports.

The structured deal that makes this work, if any: $9-12M cash at close against bear-to-base normalized EBITDA, plus an earnout up to $4-6M tied to actual three-year forward EBITDA performance at lender-recognized levels. This structure shifts execution risk to the seller, who is the party best positioned to support the operating result that justifies the premium. The seller will likely reject this structure because the cash component is materially below ask. That rejection is itself diligence: a seller unwilling to take risk on the forward operating result is signaling that the trailing financial picture is not the picture the buyer should expect post-close.

The broader lesson, applicable beyond this specific deal: premium-priced listings in service businesses with reported margins substantially above category norms are not opportunities to acquire structurally superior operating businesses. They are opportunities to overpay against a number that the seller has constructed and the lender will not recognize. The buyer's task is not to negotiate within the seller's frame. It is to build an independent valuation against sustainable normalized earnings, apply category-defensible multiples, and engage at a price that reflects that analysis. If the seller cannot meet that price, the buyer was never the seller's intended customer in the first place.

Deal Diligence is published Sundays. Issue 005 of the weekly market scan publishes Tuesday, May 12.

Not legal, financial, or investment advice. Independent verification and professional diligence required before any acquisition decision.

Sidebar: I built a free calculator this week that runs the
normalization framework above on any deal in 60 seconds — owner
add-backs, category multiples, implied valuation range, for 30+
SBA categories. Live at tools.ebitdareport.com.
Med Spa isn't yet in the category list (next update). Use the
generic medical practice or run it as custom input.